NEW YORK – The National Institute for Health and Care Excellence (NICE) in the UK on Thursday published a final draft guidance recommending that the National Health Service make available gilteritinib (Astellas' Xospata) monotherapy for patients with FLT3-mutated acute myeloid leukemia.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.